Schenkein David P has filed 67 insider transactions across 4 companies since January 2023.
Most recent transaction: a grant/award of 155 shares of REGENERON PHARMACEUTICALS, INC. ($REGN) on January 02, 2026.
Activity breakdown: 0 open-market purchases and 16 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 2, 2026 | REGENERON PHARMACEUTICALS, INC. | $REGN | Schenkein David P | Director | A | Common Stock | 155 | $0.00 | 603.0000 | 137,600,000 | 34.60% | 0.00% |
| Jan. 2, 2026 | REGENERON PHARMACEUTICALS, INC. | $REGN | Schenkein David P | Director | A | Non-Qualified Stock Option (right to buy) | 1962 | $0.00 | 1,962.0000 | 137,600,000 | 9999.99% | 0.00% |
| Aug. 1, 2025 | Prime Medicine, Inc. | $PRME | Schenkein David P | Director | A | Stock Option (right to buy) | 45000 | $0.00 | 45,000.0000 | 131,160,842 | 9999.99% | 0.03% |
| Aug. 1, 2025 | Prime Medicine, Inc. | $PRME | Schenkein David P | Director | D | Stock Option (right to buy) | 39062 | $0.00 | 0.0000 | 131,160,842 | 100.00% | 0.03% |
| Aug. 1, 2025 | Prime Medicine, Inc. | $PRME | Schenkein David P | Director | D | Stock Option (right to buy) | 45000 | $0.00 | 0.0000 | 131,160,842 | 100.00% | 0.03% |
| Aug. 1, 2025 | Prime Medicine, Inc. | $PRME | Schenkein David P | Director | A | Stock Option (right to buy) | 39062 | $0.00 | 39,062.0000 | 131,160,842 | 9999.99% | 0.03% |
| June 3, 2025 | Denali Therapeutics Inc. | $DNLI | Schenkein David P | Director | A | Stock Option (right to buy) | 18111 | $0.00 | 18,111.0000 | 164,473,772 | 9999.99% | 0.01% |
| June 4, 2025 | Prime Medicine, Inc. | $PRME | Schenkein David P | Director | A | Stock Option (right to buy) | 55000 | $0.00 | 55,000.0000 | 131,160,842 | 9999.99% | 0.04% |
| June 3, 2025 | Denali Therapeutics Inc. | $DNLI | Schenkein David P | Director | A | Common Stock | 6037 | $0.00 | 72,721.0000 | 164,473,772 | 9.05% | 0.00% |
| Jan. 2, 2025 | REGENERON PHARMACEUTICALS, INC. | $REGN | Schenkein David P | Director | A | Common Stock | 166 | $0.00 | 448.0000 | 136,000,000 | 58.87% | 0.00% |
| Jan. 2, 2025 | REGENERON PHARMACEUTICALS, INC. | $REGN | Schenkein David P | Director | A | Non-Qualified Stock Option (right to buy) | 1958 | $0.00 | 1,958.0000 | 136,000,000 | 9999.99% | 0.00% |
| Nov. 11, 2024 | Denali Therapeutics Inc. | $DNLI | Schenkein David P | Director | S | Common Stock | 27129 | $32.09 | 98,996.0000 | 169,456,988 | 21.51% | 0.02% |
| Nov. 11, 2024 | Denali Therapeutics Inc. | $DNLI | Schenkein David P | Director | S | Common Stock | 32312 | $32.87 | 66,684.0000 | 169,456,988 | 32.64% | 0.02% |
| Nov. 11, 2024 | Denali Therapeutics Inc. | $DNLI | Schenkein David P | Director | M | Stock Option (right to buy) | 47165 | $0.00 | 0.0000 | 169,456,988 | 100.00% | 0.03% |
| Nov. 11, 2024 | Denali Therapeutics Inc. | $DNLI | Schenkein David P | Director | M | Common Stock | 47165 | $18.00 | 126,125.0000 | 169,456,988 | 59.73% | 0.03% |
| June 20, 2024 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | A | Restricted stock units | 2120 | $0.00 | 2,120.0000 | 72,967,922,000 | 9999.99% | 0.00% |
| June 20, 2024 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | A | Stock options (right to buy) | 11774 | $0.00 | 11,774.0000 | 72,967,922,000 | 9999.99% | 0.00% |
| June 13, 2024 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | M | Common stock | 3388 | $0.00 | 476,096.0000 | 72,967,922,000 | 0.72% | 0.00% |
| June 13, 2024 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | M | Restricted stock units | 3388 | $0.00 | 0.0000 | 72,967,922,000 | 100.00% | 0.00% |
| June 12, 2024 | Prime Medicine, Inc. | $PRME | Schenkein David P | Director | A | Stock Option (right to buy) | 45000 | $0.00 | 45,000.0000 | 0 | 9999.99% | 0.00% |
| May 31, 2024 | Denali Therapeutics Inc. | $DNLI | Schenkein David P | Director | A | Common Stock | 5967 | $0.00 | 78,960.0000 | 137,370,897 | 8.17% | 0.00% |
| May 31, 2024 | Denali Therapeutics Inc. | $DNLI | Schenkein David P | Director | A | Stock Option (right to buy) | 17901 | $0.00 | 17,901.0000 | 137,370,897 | 9999.99% | 0.01% |
| Feb. 27, 2024 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | M | Common stock | 57471 | $31.64 | 530,179.0000 | 72,161,489,000 | 12.16% | 0.00% |
| Feb. 27, 2024 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | S | Common stock | 57471 | $34.89 | 472,708.0000 | 72,161,489,000 | 10.84% | 0.00% |
| Feb. 27, 2024 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | M | Stock option (right to buy) | 11858 | $0.00 | 57,471.0000 | 72,161,489,000 | 17.10% | 0.00% |
| Feb. 27, 2024 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | M | Stock option (right to buy) | 57471 | $0.00 | 0.0000 | 72,161,489,000 | 100.00% | 0.00% |
| Feb. 27, 2024 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | M | Common stock | 11858 | $31.64 | 484,566.0000 | 72,161,489,000 | 2.51% | 0.00% |
| Feb. 27, 2024 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | S | Common stock | 11858 | $33.60 | 472,708.0000 | 72,161,489,000 | 2.45% | 0.00% |
| Feb. 26, 2024 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | M | Common stock | 20411 | $31.64 | 493,119.0000 | 72,161,489,000 | 4.32% | 0.00% |
| Feb. 26, 2024 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | S | Common stock | 20411 | $33.19 | 472,708.0000 | 72,161,489,000 | 4.14% | 0.00% |
| Feb. 23, 2024 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | M | Stock option (right to buy) | 47731 | $0.00 | 89,740.0000 | 72,161,489,000 | 34.72% | 0.00% |
| Feb. 26, 2024 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | M | Stock option (right to buy) | 20411 | $0.00 | 69,329.0000 | 72,161,489,000 | 22.74% | 0.00% |
| Feb. 23, 2024 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | S | Common stock | 47731 | $33.05 | 472,708.0000 | 72,161,489,000 | 9.17% | 0.00% |
| Feb. 23, 2024 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | M | Common stock | 47731 | $31.64 | 520,439.0000 | 72,161,489,000 | 10.10% | 0.00% |
| Jan. 2, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Schenkein David P | Director | A | Non-Qualified Stock Option (right to buy) | 508 | $0.00 | 508.0000 | 133,100,000 | 9999.99% | 0.00% |
| Jan. 2, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Schenkein David P | Director | A | Common Stock | 42 | $0.00 | 282.0000 | 133,100,000 | 17.50% | 0.00% |
| Sept. 8, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Schenkein David P | Director | A | Non-Qualified Stock Option (right to buy) | 2739 | $0.00 | 2,739.0000 | 130,400,000 | 9999.99% | 0.00% |
| Sept. 8, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Schenkein David P | Director | A | Common Stock | 240 | $0.00 | 240.0000 | 130,400,000 | 9999.99% | 0.00% |
| June 21, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | M | Common stock | 4975 | $0.00 | 472,708.0000 | 71,256,118 | 1.06% | 0.01% |
| June 21, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | M | Restricted stock unit | 4975 | $0.00 | 0.0000 | 71,256,118 | 100.00% | 0.01% |
| June 14, 2023 | Prime Medicine, Inc. | $PRME | Schenkein David P | Director | A | Stock Option (right to buy) | 39062 | $0.00 | 39,062.0000 | 0 | 9999.99% | 0.00% |
| June 13, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | A | Restricted stock units | 3388 | $0.00 | 3,388.0000 | 71,256,118 | 9999.99% | 0.00% |
| June 13, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | A | Stock options (right to buy) | 18958 | $0.00 | 18,958.0000 | 71,256,118 | 9999.99% | 0.03% |
| April 3, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | M | Stock option (right to buy) | 16363 | $0.00 | 0.0000 | 71,256,118 | 100.00% | 0.02% |
| April 3, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | M | Common stock | 16363 | $9.05 | 484,096.0000 | 71,256,118 | 3.50% | 0.02% |
| April 3, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | S | Common stock | 16363 | $22.85 | 467,733.0000 | 71,256,118 | 3.38% | 0.02% |
| March 27, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | M | Stock option (right to buy) | 20000 | $0.00 | 16,363.0000 | 71,256,118 | 55.00% | 0.03% |
| March 27, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | S | Common stock | 20000 | $22.15 | 467,733.0000 | 71,256,118 | 4.10% | 0.03% |
| March 27, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | M | Common stock | 20000 | $9.05 | 487,733.0000 | 71,256,118 | 4.28% | 0.03% |
| March 13, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | S | Common stock | 1667 | $22.72 | 467,733.0000 | 71,256,118 | 0.36% | 0.00% |
| March 13, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | M | Stock option (right to buy) | 20000 | $0.00 | 36,363.0000 | 71,256,118 | 35.48% | 0.03% |
| March 13, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | M | Common stock | 20000 | $9.05 | 487,733.0000 | 71,256,118 | 4.28% | 0.03% |
| March 13, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | S | Common stock | 18333 | $22.47 | 469,400.0000 | 71,256,118 | 3.76% | 0.03% |
| Feb. 27, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | M | Stock option (right to buy) | 20000 | $0.00 | 56,363.0000 | 71,256,118 | 26.19% | 0.03% |
| Feb. 27, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | M | Common stock | 20000 | $9.05 | 487,733.0000 | 71,256,118 | 4.28% | 0.03% |
| Feb. 27, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | S | Common stock | 20000 | $25.37 | 467,733.0000 | 71,256,118 | 4.10% | 0.03% |
| Feb. 13, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | M | Stock option (right to buy) | 20000 | $0.00 | 76,363.0000 | 71,256,118 | 20.75% | 0.03% |
| Feb. 13, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | M | Common stock | 20000 | $9.05 | 487,733.0000 | 71,256,118 | 4.28% | 0.03% |
| Feb. 13, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | S | Common stock | 20000 | $28.62 | 467,733.0000 | 71,256,118 | 4.10% | 0.03% |
| Jan. 30, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | S | Common stock | 3300 | $29.88 | 467,733.0000 | 71,256,118 | 0.70% | 0.00% |
| Jan. 30, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | M | Stock option (right to buy) | 20000 | $0.00 | 96,363.0000 | 71,256,118 | 17.19% | 0.03% |
| Jan. 30, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | M | Common stock | 20000 | $9.05 | 487,733.0000 | 71,256,118 | 4.28% | 0.03% |
| Jan. 30, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | S | Common stock | 16700 | $29.22 | 471,033.0000 | 71,256,118 | 3.42% | 0.02% |
| Jan. 17, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | S | Common stock | 1034 | $29.49 | 467,733.0000 | 71,256,118 | 0.22% | 0.00% |
| Jan. 17, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | M | Stock option (right to buy) | 20000 | $0.00 | 116,363.0000 | 71,256,118 | 14.67% | 0.03% |
| Jan. 17, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | M | Common stock | 20000 | $9.05 | 487,733.0000 | 71,256,118 | 4.28% | 0.03% |
| Jan. 17, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Schenkein David P | Director | S | Common stock | 18966 | $28.82 | 468,767.0000 | 71,256,118 | 3.89% | 0.03% |